Drug Trial Radar · NCT00395161
The CRISIS Prevention Study
Last checked: Nov 19, 2026Latest source record: Apr 18, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
293
Actual
Start
Apr 2007
Primary completion
Nov 2009
Study completion Nov 2009
Sponsor
- Lead sponsor
- Michael DeanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Seattle Children's Hospital; Children's Hospital Los Angeles; Arkansas Children's Hospital Research Institute; Children's Hospital of Michigan; University of Pittsburgh; Children's National Research Institute; University of California, Los Angeles; Harborview Injury Prevention and Research Center
- First posted
- Nov 2, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 12 months, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Despite strict hand washing, sterile technique, and antibiotic-coated catheters, nosocomial infection and sepsis remain the leading acquired causes of morbidity and mortality in critically ill children. Subsequent use of antibiotics to treat nosocomial infection and sepsis is considered a major attributable factor in the rise of antibiotic-resistant organisms in this population of children. This study will use a double-blind, randomized, controlled trial design to test the hypothesis that daily prophylaxis with metoclopramide, zinc, selenium and glutamine will reduce nosocomial infection and sepsis in critically ill children.
Conditions
- Sepsis
Interventions
MetoclopramideDrug
0.2 mg/kg/dose IV every 12 hours
ZincDrug
one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants \< or equal to one year of age, and 20 mg/day elemental zinc for patients \> 1 year of age)
GlutamineDietary supplement
one enteral dose daily of glutamine 0.3 gm/kg/day
SeleniumDrug
one enteral dose daily of selenium (40 μg for infants \< 8 months of age, 60 μg for infants 8 to 12 months of age, 90 μg for children 1-3 years, 150 μg for children 4-8 years, 280 μg for children 9 to 13 years, and 400 μg for children \> 13 years)
salineOther
equivalent volume of intravenous saline
sterile waterOther
equivalent volume of sterile water
seleniumOther
equivalent volume of sterile water
whey-proteinDietary supplement
one enteral dose daily of whey-protein
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Primary Endpoint of This Study is the Median Time Between Admission to the PICU and Occurrence of Nosocomial Infection or Clinical Sepsis in PICU Patients Who Have Endotracheal Tubes, Central Venous Catheters, or Urinary Catheters.Time frame: 48 hours after admission until 5 days after discharged from the PICU
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
Childrens Hospital of Los Angeles
Los Angeles, California
University of California Los Angeles Medical Center
Los Angeles, California
Children's National Medical Center
Washington D.C., District of Columbia
Children's Hospital of Michigan
Detroit, Michigan
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Seattle Children's Hospital
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.